Viewing Study NCT00132873



Ignite Creation Date: 2024-05-05 @ 11:47 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00132873
Status: COMPLETED
Last Update Posted: 2013-11-25
First Post: 2005-08-18

Brief Title: Trial of Xyrem Sodium Oxybate for the Treatment of Narcolepsy
Sponsor: Jazz Pharmaceuticals
Organization: Jazz Pharmaceuticals

Study Overview

Official Title: Long-Term Open-Label Multi-Center Extension Trial of Xyrem Sodium Oxybate Oral Solution for the Treatment of Narcolepsy
Status: COMPLETED
Status Verified Date: 2013-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a long-term open-label extension of the OMC-SXB-7 trial Participants from the OMC-SXB-7 open-label trial may be entered without any requirement as to length of participation in that trial

Approximately 70 patients are expected to participate at up to 6 investigative centers located in Canada The trial will continue for up to 24 months or until marketing approval whichever occurs sooner
Detailed Description: This trial will be conducted as a long-term open-label extension of the OMC-SXB-7 trial Participants from the OMC-SXB-7 open-label trial may be entered without any requirement as to length of participation in that trial

Approximately 70 patients are expected to participate at up to 6 investigative centers located in Canada The trial will continue for up to 24 months or until marketing approval whichever occurs sooner

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None